Navigation Links
Three Batesville Casket Company Production Facilities Honored for Manufacturing Expertise by National Organizations
Date:9/26/2007

Batesville, Manchester and Vicksburg Plants Recognized as Premier Facilities by the Association for Manufacturing Excellence and IndustryWeek

Magazine

BATESVILLE, Ind., Sept. 26 /PRNewswire/ -- Batesville Casket Company, the funeral service operating unit of Hillenbrand Industries (HB), announced that its two metal manufacturing facilities and its lumber processing plant have been selected as winners in two prestigious manufacturing competitions. The rough lumber processing facility in Vicksburg, Mississippi, was named a finalist in the Best Plant competition conducted by IndustryWeek magazine. Batesville's Manchester, Tennessee, manufacturing plant and its hometown manufacturing facility in Batesville, Indiana, were named two of eight regional winners in the Manufacturing Excellence Award competition by the Association for Manufacturing Excellence.

"We are very gratified that the achievements of the Batesville, Manchester and Vicksburg teams have been recognized, especially given the caliber of the other facilities in the competition," Ken Camp, president and CEO of Batesville Casket Company, said. "But this recognition is only the by- product. The real mission of every Batesville operation has always been to take extraordinary care of our customers, be better today than we were yesterday, and to be a place where the best and brightest seek to spend a career."

"This award serves as recognition of the dedicated work ethic of our associates, our strong commitment to total customer satisfaction, and a never- ending quest for continuous improvement of our processes through lean manufacturing techniques," said Doug Kunkel, vice president of global supply chain management. "These awards provide evidence that our company is taking the necessary steps to deliver superior value to our customers and is realizing our goal of remaining the preferred supplier of high quality caskets to funeral homes throughout North
'/>"/>

SOURCE Batesville Casket Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Nobel Prize for Medicine shared by Three scientists
3. Biotechnology industry expected to grow into a three billion dollar industry by 2002
4. Baltimore doctors perform three simultaneous kidney transplants
5. FDA gives “black box warning” against three asthma drus
6. Three Tropical Parasites Genetic Code Unravelled
7. The Future Pattern Of Weight Gain Is Laid As Early As Three Years Of Age
8. Smoking Increases The Risk Of Heart Disease By Three Times
9. Three Sisters Have One Baby and Make History
10. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
11. Three More Bird Flu Cases Reported By China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...ns of Children Still in Danger, NEW YORK, May 16 ...dvertising Council today announced a partnership t...ic service announcements (PSAs) filmed by A-List,c... Joel Madden, David,Duchovny, Tea Leoni, and Paul ...r cyclone. The Ad Council is distributing the new ...
(Date:5/16/2008)...wswire-FirstCall/ -- Nationwide,Health Properties,...of David,M. Boitano to Senior Vice President and S...ous contribution to NHP over the last several year... diversification strategy,successes. Dave has been...stments for NHP, leveraging his vast experience an...
(Date:5/16/2008)...Call/ -- CryoCor, Inc. (Nasdaq:,CRYO), a medical d...arrhythmias, announced today that on May 8, 2008, ...a complaint in the Superior Court of the State,of ...nts each member of the,Board of Directors of CryoC... complaint is styled Secondido, et al. v. CryoCor,...
(Date:5/16/2008)...ed to community physicians, audit finds , ...s between major academic cancer centers and commun...ead cancer treatment advances, say researchers at ... new cancer treatments are created at major academ...munity hospitals, noted the researchers, who condu...
Breaking Medicine News(10 mins):Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2
... foreign medical schools, including those from Ind...apore starting next year, the health ministry said...es like the Philippines, India and Myanmar, have b...octors. The Singapore Medical Council has allowed...
...n the process of circumcision turns out to be the ...-health impact of neo-natal circumcision has recei...cision on sexual function in the adult male have r...tion. But now, a recent study, by M. Sorrels and ...
...cialite's younger sister Nicky in hysterics, and s...al ward of the LA facility . Talking about the tr...d that 'it is really tough', for they only get to ..."It's tough. It is. It's just one hour a week: 30 ...
...n she became HIV infected. Six years later, she is...le and teaching them how to live with the disease ...three years, 27-year-old Hina from Davangere distr...itive people, counselling them on how to overcome ...
Other Medicine News:Health News:AIDS Patient Helps Others Lead a Positive Life 2
(Date:5/16/2008)...ata from three studies,evaluating associations bet...d the rate of blood transfusions, as well as the p...r erythropoiesis-stimulating agents (ESAs),in Medi...e presented at the,American Society of Clinical On... meeting will take place in Chicago from May 30 to...
(Date:5/16/2008)...ion of a Small Molecule with Dem...., May 16 /- Nektar,Therape...oday from a Phase 1,study of NKTR- 102, PEGylated ...activity in patients with refractory solid tumors....olecule PEGylation technology,produced an increase...
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference 7187 1STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference 7187 2UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy 7185 1UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy 7185 2UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy 7185 3Nutraceutical Reports 2007 Fiscal Year End Results 7183 1Nutraceutical Reports 2007 Fiscal Year End Results 7183 2Nutraceutical Reports 2007 Fiscal Year End Results 7183 3Nutraceutical Reports 2007 Fiscal Year End Results 7183 4Nutraceutical Reports 2007 Fiscal Year End Results 7183 5Nutraceutical Reports 2007 Fiscal Year End Results 7183 6Medco Announces Two For One Stock Split 7181 1Medco Announces Two For One Stock Split 7181 2Medco Announces Two For One Stock Split 7181 3Medco Announces Two For One Stock Split 7181 4Medco Announces Two For One Stock Split 7181 5
...ented at the ASCO Cancer Conference, NORTH HOLLYWO.../,-- The International Myeloma Foundation (IMF)-su...y and support for myeloma patients,families, rese...,follow-up to a Phase 3 multi- national clinical t...E(R) improves the probability of,survival by 41%. ...
...ANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - Repros...ne results of a,six month U.S. Phase 3 study of An...e normal testicular function in men with,secondary...inferiority in all the endpoints of the study, com... treatment for low,testosterone., Study Details an...
Other Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 2Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 3Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 4Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 5
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio
Magnetic separation is a method for isolating antibodies, antigens, lectins, enzymes, nucleic acids and cells using affinity binding, while retaining biological activity. Streptavidin has been coated
1 m Dynabeads with covalently bound recombinant streptavidin, allowing capture of any biotinylated target. The Dynabeads® MyOne™ have a large surface area, high capacity, magnetic pull and
Medicine Products: